8-K: Apyx Medical Q2 2025: Revenue Guidance Raised

Apyx Medical Corporation reported Q2 2025 financial results, including a reduced net loss and increased full-year revenue guidance driven by strong initial demand for its new AYON Body Contouring System.

Summary

• Total revenue for the second quarter of 2025 was $11.4 million, a decrease from $12.1 million in the comparable period last year.
• Advanced Energy revenue was relatively flat year-over-year at $9.7 million in Q2 2025, compared to $9.8 million in Q2 2024.
• OEM revenue decreased by 28.5% year-over-year to $1.7 million in Q2 2025.
• Net loss attributable to stockholders decreased by $2.8 million, or 42%, to $3.8 million in Q2 2025, compared with $6.6 million in Q2 2024.
• Adjusted EBITDA loss decreased by $2.3 million, or 54%, to $2.0 million for Q2 2025, compared with $4.3 million for Q2 2024.
• The AYON Body Contouring System received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
• Initial U.S. sales of AYON were launched, placing units with key surgeons, with customer demand exceeding expectations; a commercial launch is planned for September 2025.
• Commercial sales of Renuvion in China initiated, with strong clinical interest and completed initial procedures.
• Full-year 2025 total revenue guidance was increased to a range of $50.0 million to $52.0 million, up from the previous guidance of $47.6 million to $49.0 million.
• Full-year 2025 Advanced Energy revenue is expected to be in the range of $42.0 million to $44.0 million, up from previous guidance of $39.6 million to $41.0 million.
• Full-year 2025 OEM revenue is expected to be approximately $8.0 million.
• Total operating expenses for the full year 2025 are expected to be less than $40.0 million.

Sentiment

Score: 8

Explanation: The company demonstrated significant improvements in profitability metrics (reduced net loss and adjusted EBITDA loss) and gross margin. The successful initial launch of the AYON system, exceeding customer expectations, and the subsequent upward revision of full-year revenue guidance are strong positive indicators for future growth. International expansion into China also presents a substantial market opportunity. While current quarter revenue saw a slight decline, the forward-looking statements and operational efficiencies suggest a positive trajectory.

Positives

• Net loss attributable to stockholders decreased by $2.8 million (42%) to $3.8 million in Q2 2025, indicating improved profitability.
• Adjusted EBITDA loss decreased by $2.3 million (54%) to $2.0 million in Q2 2025, reflecting enhanced operational efficiency.
• Gross margin increased to 62.3% in Q2 2025 from 61.7% in Q2 2024, primarily due to a favorable product mix with Advanced Energy comprising a higher percentage of total sales.
• Operating expenses decreased by $3.4 million to $9.7 million in Q2 2025, driven by reductions in salaries, SG&A, R&D, and professional services.
• The AYON Body Contouring System received FDA 510(k) clearance, enabling its commercialization in the U.S.
• Initial U.S. sales of AYON exceeded customer expectations, leading to an accelerated commercial launch plan.
• Full-year 2025 total revenue guidance was increased to $50.0 million $52.0 million, reflecting confidence in future sales growth.
• Full-year 2025 Advanced Energy revenue guidance was increased to $42.0 million $44.0 million, indicating strong performance expectations for the core segment.
• Successful initiation of commercial sales for Renuvion in China, a significant international market.
• Strengthened management team with the appointments of John Featherstone as VP of North American Sales and Simon Davies as Director of International Sales, Europe and Asia-Pacific.

Negatives

• Total revenue decreased to $11.4 million in Q2 2025 from $12.1 million in Q2 2024, representing a 6.4% year-over-year decline.
• OEM revenue decreased significantly by 28.5% to $1.7 million in Q2 2025, primarily due to reduced sales volume to existing customers.
• Domestic revenue decreased by 10.5% to $7.776 million in Q2 2025.
• Gross profit decreased to $7.1 million in Q2 2025 from $7.5 million in Q2 2024, despite an improved gross margin percentage.
• Interest income decreased by $0.2 million in Q2 2025 compared to the prior year period.
• Cash and cash equivalents decreased to $29.301 million as of June 30, 2025, from $31.741 million as of December 31, 2024.
• Trade accounts receivable decreased to $11.248 million as of June 30, 2025, from $15.480 million as of December 31, 2024.

Risks

• Inability to gain requisite regulatory approvals for products from the FDA and other governmental and regulatory bodies, both domestically and internationally.
• Sudden or extreme volatility in commodity prices and availability, including supply chain disruptions, component shortages, manufacturing disruptions, or logistics challenges.
• Changes in general economic, business, or demographic conditions or trends.
• Changes in and effects of the geopolitical environment.
• Liabilities and costs which may be incurred from pending or threatened litigations, claims, disputes, or investigations.
• Impact of macroeconomic or geopolitical matters on financial performance.

Future Outlook

The company revised its full-year 2025 total revenue guidance upwards to $50.0 million to $52.0 million, driven by stronger-than-expected initial demand for the newly FDA-cleared AYON Body Contouring System, which is set for a nationwide commercial launch in September 2025. Advanced Energy revenue guidance was also increased to $42.0 million to $44.0 million. The company anticipates continued progress in the Chinese market for Renuvion and believes Renuvion is well-positioned to address loose skin post-weight loss for patients on GLP-1 drugs. Operating expenses are projected to be less than $40.0 million for the full year.

Management Comments

• "Customer interest in AYON quickly exceeded our expectations for this early stage of the rollout, with surgeons selected to be early adopters already installing our system and performing initial procedures."
• "As a result, we have increased our revenue guidance for the full year 2025 to $50.0 million to $52.0 million and look forward to a nationwide launch of AYON in September."
• "Looking to our international commercial strategy, we have made significant progress in bringing Renuvion to China, which is the the third largest market for aesthetic surgery."
• "We believe Renuvion is well-position to become the standard-of-care for the rapidly growing patient population on GLP-1 drugs who choose to address their loose skin post-weight loss."
• "These developments underscore the strength of our product portfolio and the scale of the market opportunity ahead of us."

Industry Context

The company is expanding its presence in the aesthetic surgery market with the new AYON Body Contouring System and the international commercialization of Renuvion, particularly in China, which is noted as the third largest market for aesthetic surgery. The company also highlights a strategic positioning of Renuvion to address the growing patient population using GLP-1 drugs for weight loss, who may seek solutions for loose skin, indicating an awareness of emerging market trends and a proactive approach to market capture.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to reduced losses, improved profitability, successful new product launch, and increased revenue guidance.
• Customers (Surgeons/Patients): Access to new advanced body contouring technology (AYON) and expanded availability of Renuvion in new markets like China, offering more treatment options.
• Employees: Strengthened management team and potential for growth could lead to job stability and opportunities.
• Suppliers: Continued demand for components for Renuvion and AYON systems.
• Creditors: Improved financial health (reduced losses) could enhance creditworthiness.

Next Steps

• Nationwide commercial launch of the AYON Body Contouring System in September 2025.
• GlamMoon Medical Technology to continue ramping up targeted sales and marketing campaign for Renuvion in China.
• Shipping the balance of the AYON system in the third and fourth quarters for customers who pre-ordered the Apyx One Console.
• Management to host a conference call on August 7, 2025, at 4:30 p.m. ET to discuss results and host a Q&A session.

Key Dates

Recommendation

The company reported a significant reduction in net loss and adjusted EBITDA loss, indicating improved operational efficiency and a clearer path to profitability. The successful initial launch of the AYON Body Contouring System, which exceeded customer expectations, and the subsequent upward revision of full-year revenue guidance are strong catalysts for future growth. Expansion into the large Chinese aesthetic market with Renuvion and strategic positioning for the GLP-1 post-weight loss market further enhance long-term prospects. Despite a slight Q2 revenue dip, the positive forward-looking indicators and improved financial health make this a compelling investment opportunity.

Keywords

Apyx Medical, APYX, Renuvion, AYON Body Contouring System, aesthetic surgery, medical devices, FDA clearance, financial results, Q2 2025, revenue guidance, China market, GLP-1 drugs, tissue contraction, fat removal, helium plasma, radiofrequency